Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia
- Conditions
- Xerostomia
- Interventions
- Procedure: lipoaspirationDrug: Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)
- Registration Number
- NCT05857358
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Brief Summary
The main objective of this study is to evaluate the tolerance and safety of autologous adipose-derived stromal vascular fraction injected in accessory salivary glands for treatment of autoimmune xerostomia in terms of adverse reactions through day 14 (D14).
- Detailed Description
Autoimmune xerostomia is a disabling condition affecting mostly patients suffering from Sjögren's disease, systemic lupus erythematosus, rheumatoid arthritis and systemic xerostomia.
Local therapies and systemic drug treatments (picarpine) remain the gold standards but have limited effects upon salivary flow action and many adverse effects.
Stem cell therapies and notably adipose tissue-derived stromal cells have shown promising potential for tissue repair. Autologous uncultured adipose-derived stromal vascular fraction (AD-SVF) is recognized as an easily accessible (by a standard lipoaspiration to obtain adipose tissue, from which AD-SVF are isolated by centrifugation), safe and well tolerated source of cells with angiogenic, anti-inflammatory, immunomodulatory and regenerative properties.
The purpose of our AD-SVF phase I trial is to evaluate, first the tolerance of autologous AD-SVF cells locally injected in the oral cavity and second their capability to improve the salivary function.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 18
- Patients from 18 to 65 years.
- Patients suffering from xerostomia and autoimmune disease including : Gougerot-Sjögren disease according to AC/EULAR criteria and Secondary Gougerot-Sjögren syndrome related to systemic diseases (sclerodermia, rheumatoid arthritis, systemic lupus erythematosus...)
- Xerostomia visual scale (6-item visual analogue scale questionnaire) for assessment of salivary dysfunction : score ≥ 30/60
- Informed consent to participate (with signature)
- Negative β -HCG test and effective contraception for women being able to get pregnant
- Affiliation to the social security system
- Medical history of head and neck neoplasia
- Recent (<3 months) medication inducing and aggravating xerostomia : Standard treatment with tricyclic antidepressant and/or antipsychotics
- Body Mass Index < 18
- Active smoking (> 5 cigarettes a day)
- Active infectious disease and/or active viral serologies (HIV, HCV, HBV, HTLV I/II, TPHA/VDRL)
- Coagulation disorders including anticoagulant and antiplatelet treatment
- Any temporary or definitive contraindication due to any medical or surgical unstable condition
- Allergy to local anesthesia and/or albumin
- Pregnant or breastfeeding women
- Adult protected by the law (tutorship and curatorship)
- Patients already enrolled in another study
- Patients under 18 years of age
- Person deprived of liberty
- Patient non-affiliated to the social security
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Adult patients suffering from xerostomia and autoimmune disease Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF) Xerostomia treatment consist of 3 steps (including 2 surgical steps) in the Hospital de la Conception of Marseille, in the same ward : * The plastic/maxillofacial surgeon : collects the adipose tissue, and transfers it to the cell therapy unit; * The cell therapy unit processes and controls the experimental product (adipose-derived stromal vascular fraction; AD-SVF) from the harvested adipose tissue. The AD-SVF batch is nominatively transported to the surgeon; * The maxillofacial surgeon injects the AD-SVF without delay under local anesthesia. Adult patients suffering from xerostomia and autoimmune disease lipoaspiration Xerostomia treatment consist of 3 steps (including 2 surgical steps) in the Hospital de la Conception of Marseille, in the same ward : * The plastic/maxillofacial surgeon : collects the adipose tissue, and transfers it to the cell therapy unit; * The cell therapy unit processes and controls the experimental product (adipose-derived stromal vascular fraction; AD-SVF) from the harvested adipose tissue. The AD-SVF batch is nominatively transported to the surgeon; * The maxillofacial surgeon injects the AD-SVF without delay under local anesthesia.
- Primary Outcome Measures
Name Time Method Intensity of adverse reactions at the injection site at day 3 3 days 3 days after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with phone assessment.
Intensity of adverse reactions at the injection site at day 7 7 days 7 days after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at day 14 14 days 14 days after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the injection site at day 1 1 day 1 day after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with phone assessment
Intensity of adverse reactions at the harvesting site at day 1 1 day 1 day after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with phone assessment.
Intensity of adverse reactions at the injection site at day 14 14 days 14 days after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at day 3 3 days 3 days after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event, through an adapted report form with phone assessment.
Intensity of adverse reactions at the harvesting site at day 7 7 days 7 days after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event, through an adapted report form with clinical assessment.
- Secondary Outcome Measures
Name Time Method Intensity of adverse reactions at the injection site at month 3 3 months 3 months after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at month 1 1 month 1 month after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the injection site at day 15 15 days 15 days after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the injection site at month 1 1 month 1 month after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the injection site at month 7 7 months 7 months after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at day 15 15 days 15 days after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the injection site at month 6 6 months 6 months after ADSVF injection, a subjective evaluation will be done by the patient of lip sensibility, pain, oedema or ecchymosis bleeding or haematoma, bleeding or haematoma, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at month 3 3 months 3 months after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at month 6 6 months 6 months after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with clinical assessment.
Intensity of adverse reactions at the harvesting site at month 7 7 months 7 months after ADSVF injection, a subjective evaluation will be done by the patient of pain, oedema or ecchymosis bleeding or haematoma, inflammation or infection, other event through an adapted report form with clinical assessment.
efficacy of AD-SVF at month 3 3 months Salivary flow will be collected after stimulation 3 months after the injection. It is expressed in milliliter by minutes after 5 minutes of collect, and oligoptyalism isdefined by a salivary flow \< 0.1 mL/mn at rest, and \< 0.7 ml/mn after stimulation.
efficacy of AD-SVF at month 6 6 months Salivary flow will be collected after stimulation 6 months after the injection. It is expressed in milliliter by minutes after 5 minutes of collect, and oligoptyalism isdefined by a salivary flow \< 0.1 mL/mn at rest, and \< 0.7 ml/mn after stimulation.
Change in dryness of oral mucosa 3 months Change in dryness of oral mucosa will be assessed from Clinical Oral Dryness Score (CODS) based on 10 items realized before and, 3 and 6 months after the injection.
primary efficiency of AD-SVF iin term of glands reparation process/repair (Minor salivary gland biopsy) 6 months A minor salivary gland biopsy will be done under local anaesthesia 6 months after the injection. Then, an Histological analysis (4 grades Chilson-Mason score) of minor salivary gland biopsy will be performed.
efficacy of AD-SVF at month 1 1 month Salivary flow will be collected after stimulation 1 month after the injection. It is expressed in milliliter by minutes after 5 minutes of collect, and oligoptyalism isdefined by a salivary flow \< 0.1 mL/mn at rest, and \< 0.7 ml/mn after stimulation.
Change in xerostomia Visual Analogic Scale (VAS) 6 months Change in VAS will be assessed from a 6-items questionnaire scored from 0 to 10 (increasing gravity) according to Likert scale.